1-20 of 70
Richard F. Little
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Timothy S. Fenske, Xin Victoria Wang, Brian G. Till, Kristie A. Blum, Matthew Lunning, Hillard M. Lazarus, Paul A.S. Fishkin, Lale Kostakoglu Shields, David W. Scott, Ann S. LaCasce, Patrick B. Johnston, Amanda F. Cashen, Leslie L. Popplewell, Robert M. Dean, Nausheen Ahmed, Nirav N. Shah, Nina D. Wagner-Johnston, Boyu Hu, Bhagirathbhai R. Dholaria, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood
Blood (2024) 144 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2024-212973
Published: 2024
Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Clinical Trials & Observations
Mitchell R. Smith, Opeyemi A. Jegede, Peter Martin, Brian G. Till, Samir S. Parekh, David T. Yang, Eric D. Hsi, Thomas Witzig, Sandeep Dave, David Scott, Curtis Hanson, Lale Kostakoglu Shields, Nizar Abdel-Samad, Carla Casulo, Nancy L. Bartlett, Paolo F. Caimi, Tareq Al Baghdadi, Kristie A. Blum, Mark D. Romer, David J. Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood
Blood (2024) 144 (10): 1083–1092.
https://doi.org/10.1182/blood.2024023962
Published: 2024
Includes: Supplemental data
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Sharon M. Castellino, Hongli Li, Alex F. Herrera, Angela Punnett, Michael Leblanc, Susan K Parsons, David Hodgson, Frank Keller, Richard A. Drachtman, Adam Lamble, Christopher J. Forlenza, Andrew Doan, Sarah C. Rutherford, Andrew M Evens, Richard F. Little, Malcolm A. Smith, Joo Y Song, Sonali M. Smith, Jonathan W. Friedberg, Kara M. Kelly
Journal: Blood
Blood (2023) 142 (Supplement 1): 610.
https://doi.org/10.1182/blood-2023-180107
Published: 2023
Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett
Journal: Blood
Blood (2023) 142 (Supplement 1): 437.
https://doi.org/10.1182/blood-2023-173742
Published: 2023
Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Selina M Luger, Zhuoxin Sun, Ryan J Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevckis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Matthew J. Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W Pratz, Shira N. Dinner, Noelle V. Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L Uy, Deepa Jeyakumar, Tara L Lin, Cheryl L. Willman, Daniel J. DeAngelo, Elad Sharon, Richard F. Little, Harry P. Erba, Richard M Stone, Charles G. Mullighan, Mark R. Litzow, Martin S. Tallman
Journal: Blood
Blood (2023) 142 (Supplement 1): 2877.
https://doi.org/10.1182/blood-2023-189648
Published: 2023
Journal Articles

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Rory M. Shallis, Ondrej Blaha, Stephanie Halene, Lourdes Mendez, Nikolai A. Podoltsev, Anne Caldwell, Jan Philipp Bewersdorf, Richard F. Little, Richard Piekarz, Mrinal M. Patnaik, Steven D. Gore, Amer M. Zeidan
Journal: Blood
Blood (2023) 142 (Supplement 1): 3252.
https://doi.org/10.1182/blood-2023-182814
Published: 2023
Journal Articles

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Mark R. Litzow, Zhuoxin Sun, Elisabeth Paietta, Ryan J. Mattison, Hillard M Lazarus, Jacob M. Rowe, Daniel A. Arber, Charles G. Mullighan, Cheryl L Willman, Yanming Zhang, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Keith W. Pratz, Shira Dinner, Noelle V. Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L. Uy, Deepa Jeyakumar, Tara L. Lin, Richard F. Little, Selina M. Luger, Martin S. Tallman
Journal: Blood
Blood (2022) 140 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2022-171751
Published: 2022
Journal Articles

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Jan Philipp Bewersdorf, Rory Michael Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard Piekarz, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9084–9086.
https://doi.org/10.1182/blood-2022-158626
Published: 2022
Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Richard F. Little, Megan Othus, Sarit Assouline, Sherry Ansher, Ehab L. Atallah, R. Coleman Lindsley, Boris Freidlin, Steven D. Gore, Lyndsay Harris, Christopher S. Hourigan, S. Percy Ivy, Shahanawaz Jiwani, Erin Langan, Selina M. Luger, Laura C. Michaelis, Olatoyosi Odenike, David Patton, Miguel-Angel Perales, Jerald P. Radich, Bhanu Ramineni, Jesse J. Salk, Patrick Stiff, Wendy Stock, Richard M. Stone, Geoffrey L. Uy, P. Mickey Williams, Brent L. Wood, Katherine H Worthington, Laura M Yee, Amer M. Zeidan, Jianqiao Zhang, Mark R. Litzow, Harry P. Erba
Journal: Blood
Blood (2022) 140 (Supplement 1): 9057–9060.
https://doi.org/10.1182/blood-2022-169307
Published: 2022
Journal Articles

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Anna Moseley, Boris Freidlin, Rory Michael Shallis, Amer M. Zeidan, David A. Sallman, Richard F. Little, Harry P. Erba, Michael L. Leblanc, Megan Othus
Journal: Blood
Blood (2022) 140 (Supplement 1): 8932–8933.
https://doi.org/10.1182/blood-2022-170376
Published: 2022
Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Clinical Trials & Observations
Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, Elisabeth M. Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry Erba, Richard M. Stone, Mark Litzow, Martin Tallman, Neil E. Kay
Journal: Blood
Blood (2022) 140 (2): 112–120.
https://doi.org/10.1182/blood.2021014960
Published: 2022
Includes: Supplemental data
Journal Articles

Evaluation of a Rapid Automated Next Generation Sequencing Assay for Precision Medicine in Acute Myeloid Leukemia

Georgia M. Andrew, Laura W. Dillon, Maria Saeed, Ting-Chia Chang, Srikrishna K. Narava, Erin M. Mosher, Marvin S. Majano, Anna Lee-Fong, John N. Zhang, Marina Sedova, Jiajie Huang, Vinay K. Mittal, Andrew G. Hatch, Jingwei Ni, Denis Kaznadzey, Seth Sadis, Jeffery M. Smith, Richard F. Little, Lyndsay Harris, James H. Doroshow, P. Mickey Williams, Shahanawaz Jiwani, Christopher S. Hourigan
Journal: Blood
Blood (2021) 138 (Supplement 1): 4444.
https://doi.org/10.1182/blood-2021-148926
Published: 2021
Journal Articles

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric D. Hsi, Richard F. Little, Steven D. Gore, Anusha Vallurupalli, Daniel J Landsburg, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard
Journal: Blood
Blood (2021) 138 (Supplement 1): 523.
https://doi.org/10.1182/blood-2021-151266
Published: 2021
Journal Articles

S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements

Elizabeth A Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh, Rebecca L. Olin, Norah Lynn Henry, Hildy Dilon, Richard F. Little, Cara Laubach, Michael L. Leblanc, Jonathan W. Friedberg, Sonali M. Smith
Journal: Blood
Blood (2021) 138 (Supplement 1): 3565.
https://doi.org/10.1182/blood-2021-148193
Published: 2021
Journal Articles

Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)

Amer M. Zeidan, Kevin Roopcharan, Jerry P. Radich, Jan Philipp Bewersdorf, Vijaya R. Bhatt, Elad Sharon, Richard F. Little, Steven D. Gore, Anne Caldwell, Selina M. Luger, Mark R. Litzow
Journal: Blood
Blood (2021) 138 (Supplement 1): 3613.
https://doi.org/10.1182/blood-2021-145015
Published: 2021
Journal Articles

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison M Booth, Diane Feldman, Elie G Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla A. Heerema, Cecelia Miller, Gerard Lozanski, Richard F. Little, Brian T. Hill, Wei Ding, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 3728.
https://doi.org/10.1182/blood-2021-151471
Published: 2021
Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 639.
https://doi.org/10.1182/blood-2021-153146
Published: 2021
Journal Articles

Treatment Outcomes and Prognostic Factors in 40 Patients with Primary Effusion Lymphoma

Krithika Shanmugasundaram, Ramya Ramaswami, Anaida Widell, Ralph Mangusan, Elaine S. Jaffe, Stefania Pittaluga, Hao-Wei Wang, Vickie Ann Marshall, Denise Whitby, Richard F. Little, Mark N. Polizzotto, Thomas S. Uldrick, Robert Yarchoan, Kathryn A. Lurain
Journal: Blood
Blood (2021) 138 (Supplement 1): 1437.
https://doi.org/10.1182/blood-2021-151409
Published: 2021
Journal Articles

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Priyanka A Pophali, Xin Victoria Wang, Fengmin Zhao, Neil E. Kay, Curtis A. Hanson, Mary L. Thomas, Susan M. O'Brien, Jacqueline Barrientos, Elisabeth M. Paietta, Jose F. Leis, Cong Christine Zhang, Steven Coutre, Paul M. Barr, Amanda Cashen, Anthony R. Mato, Avina Singh, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman, Tait Shanafelt, Lynne I. Wagner
Journal: Blood
Blood (2021) 138 (Supplement 1): 1562.
https://doi.org/10.1182/blood-2021-150462
Published: 2021